ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 08 2020 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will present
at the H.C. Wainwright 22nd Annual Global Investment
Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET.
A live audio webcast of the presentation can be accessed through
the Investors section of the Company's website
at www.ChemoCentryx.com. A replay of the webcast will be
available on the Company's website for two weeks following the live
presentation.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications for inflammatory and autoimmune diseases and cancer.
ChemoCentryx targets the chemokine and chemoattractant systems to
discover, develop and commercialize orally administered, targeted
therapies. ChemoCentryx’s lead drug candidate, avacopan, completed
a pivotal Phase III trial in ANCA-associated vasculitis and a New
Drug Application (NDA) has been submitted to the FDA. ChemoCentryx
is also developing avacopan for the treatment of patients with C3
glomerulopathy (C3G) and hidradenitis suppurativa (HS). The Company
also has early stage drug candidates that target chemoattractant
receptors in other inflammatory and autoimmune diseases and in
cancer, including an orally-administered small molecule checkpoint
inhibitor of PD-1/PD-L1. For more information, please
visit www.chemocentryx.com
Contacts:
Susan M. KanayaExecutive Vice President,Chief
Financial and Administrative Officerinvestor@chemocentryx.com
Media: Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Steven Klass, Burns
McClellan212.213.0006Sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024